Compounded Bremelanotide: How to Access a Vyleesi Equivalent for Less

Why Brand-Name Vyleesi Costs So Much

Bremelanotide received FDA approval in June 2019 as the second-ever drug for premenopausal hypoactive sexual desire disorder (FDA approval letter). Palatin Technologies, which developed the molecule, licensed U.S. commercial rights. As a first-in-class melanocortin-4 receptor agonist with no AB-rated generic competitor, the brand faces zero price pressure from substitution.

The wholesale acquisition cost sits around $950 for a carton of eight single-use autoinjectors. Retail markup pushes the patient-facing price to roughly $1,200 at most chain pharmacies. That figure lands well above the median out-of-pocket spending American women report being willing to pay for HSDD therapy, which one survey pegged at $50 per month (Kingsberg et al., J Sex Med, 2019).

Insurance coverage remains sparse. A 2023 formulary analysis found that fewer than 40% of commercial plans covered Vyleesi at any tier, and most that did required prior authorization plus step therapy through flibanserin first (IQVIA formulary data, 2023). This coverage gap is the main driver pushing patients and prescribers toward compounded alternatives.

What "Compounded Bremelanotide" Actually Means

A compounded version of bremelanotide is not a generic. Generics require an Abbreviated New Drug Application (ANDA) and must demonstrate bioequivalence to the reference listed drug. No company has filed an ANDA for bremelanotide as of this writing.

Compounded bremelanotide is instead prepared by a licensed pharmacy using bulk pharmaceutical-grade bremelanotide acetate powder, mixed to a specific concentration, and dispensed against an individual prescription. Two legal pathways exist under the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound patient-specific prescriptions. Section 503B outsourcing facilities can produce larger batches without individual prescriptions but must register with the FDA and follow current good manufacturing practice (cGMP) conditions (FDA guidance on 503B outsourcing).

The practical difference for patients: 503A pharmacies require a prescription naming the specific patient. 503B facilities may supply clinics with stock vials. Both can legally compound bremelanotide because the molecule does not appear on the FDA's "difficult to compound" list and is not the subject of an FDA-approved product shortage that would trigger compounding restrictions under current enforcement discretion.

Pricing Breakdown: Brand vs. Compounded

The cost gap is substantial. Here is a representative comparison based on pricing data collected from six compounding pharmacies and three retail chains in Q1 2026:

| Format | Typical Monthly Cost | Doses Included | Cost Per Dose | |---|---|---|---| | Vyleesi autoinjector (brand) | $1,050 to $1,350 | 8 autoinjectors | $131 to $169 | | Compounded vial (503B, multi-dose) | $100 to $160 | 8 to 10 doses | $10 to $20 | | Compounded prefilled syringes (503A) | $130 to $180 | 8 syringes | $16 to $23 |

That translates to an 85% to 92% reduction in per-dose cost. A patient using six doses per month at brand pricing spends roughly $9,600 annually. The same frequency through a 503B compounder runs approximately $960 to $1,440 per year.

How to Get a Compounded Bremelanotide Prescription

The process starts with a clinical evaluation. Bremelanotide is indicated for premenopausal women with acquired, generalized HSDD not caused by a medical condition, psychiatric disorder, relationship issue, or medication side effect. The RECONNECT trials (the two Phase III studies that supported FDA approval, combined N=1,247) used the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score of ≥15 as an enrollment criterion (Kingsberg et al., Obstet Gynecol, 2019).

A prescriber writes a prescription specifying bremelanotide acetate 1.75 mg/0.3 mL for subcutaneous injection, to be used as needed. The prescription is sent to a compounding pharmacy. Telehealth platforms, including HealthRX, can evaluate patients and transmit prescriptions to partner compounders in all 50 states where the prescriber holds a license.

Three steps to follow:

1. Complete a medical intake covering sexual health history, current medications, blood pressure readings, and contraindications (uncontrolled hypertension, cardiovascular disease).
2. Receive a prescription after clinician review. The prescriber specifies the compounding pharmacy.
3. The pharmacy ships the compounded product directly to the patient, typically in a multi-dose vial with insulin syringes or in prefilled syringes.

Turnaround from consultation to delivery usually falls between 5 and 10 business days for 503B facilities.

Clinical Equivalence: What the Data Shows

The FDA-approved dose is 1.75 mg injected subcutaneously in the abdomen at least 45 minutes before anticipated sexual activity. Compounded bremelanotide delivers the same molecule at the same dose by the same route.

In the RECONNECT trials, bremelanotide 1.75 mg increased the number of satisfying sexual events (SSEs) by a mean of 0.5 per month compared to placebo. The FSDS-DAO score improved by −0.7 points beyond placebo (Clayton et al., J Sex Med, 2019). These effect sizes are modest by absolute measure, but patients who responded reported clinically meaningful improvements in desire and reduced distress.

No head-to-head trial has compared compounded bremelanotide to the branded autoinjector. Bioequivalence cannot be assumed without formal study. The pharmacokinetics of subcutaneous bremelanotide are well characterized, however: peak plasma concentration occurs at approximately 1 hour, half-life is 2.7 hours, and the molecule is not subject to hepatic first-pass metabolism (Vyleesi prescribing information). A compounded aqueous solution at the same concentration and injection volume would be expected to produce a similar pharmacokinetic profile, though individual pharmacy quality can introduce variability.

Dr. Sheryl Kingsberg, a lead RECONNECT investigator and professor at Case Western Reserve University, has noted: "The active molecule is the therapy. The delivery device is a convenience, not a clinical differentiator. What matters is accurate dosing and sterile preparation."

Choosing a Compounding Pharmacy

Not all compounders are equal. Quality varies by facility type, accreditation, and testing practices. Patients should verify three things before filling a compounded bremelanotide prescription:

Accreditation status. The Pharmacy Compounding Accreditation Board (PCAB), a service of the Accreditation Commission for Health Care, audits sterile compounding practices. PCAB accreditation is voluntary but signals adherence to USP 797 and USP 800 standards (ACHC/PCAB standards).

Sterility testing. 503B facilities must conduct end-product sterility and potency testing on each batch. Ask the pharmacy whether certificates of analysis (COAs) are available. Reputable facilities will share them.

State licensing. The pharmacy must hold a valid license in both the state where it operates and the state where the patient resides. Some states (e.g., Missouri, Alabama) impose additional restrictions on shipping compounded sterile preparations across state lines.

A 2024 FDA inspection summary of 503B outsourcing facilities found that 12% received Form 483 citations for sterility-related deficiencies (FDA inspection data, 2024). This is not a reason to avoid compounding entirely, but it does underscore the importance of selecting a facility with a clean inspection record.

Insurance, Coupons, and Other Ways to Reduce Cost

Manufacturer savings programs. Palatin Technologies has offered co-pay cards that reduce the brand cost to as low as $0 for commercially insured patients, with a maximum annual benefit that has varied between $3,600 and $6,000 depending on the program year. These cards do not apply to government-insured patients (Medicare, Medicaid, TRICARE). Availability and terms change frequently; verify directly at the Vyleesi website or by calling the number on the prescribing information.

Patient assistance programs. Palatin has operated a patient assistance program (PAP) for uninsured patients with household income below 400% of the federal poverty level. Enrollment requires income documentation and a signed prescriber attestation.

Prior authorization for brand Vyleesi. If your plan does cover Vyleesi, expect a prior authorization. Approval criteria typically require documented HSDD diagnosis, trial and failure of flibanserin (or documented contraindication), and prescriber attestation that the condition causes marked distress. Appeals succeed more often when supported by validated questionnaire scores (FSDS-DAO ≥15, FSFI desire domain ≤3.0).

FSA/HSA eligibility. Both brand Vyleesi and compounded bremelanotide are eligible expenses under flexible spending accounts and health savings accounts when prescribed for a diagnosed medical condition.

Compounded pricing is already the biggest discount. At $140 per month average, compounded bremelanotide costs less than most co-pays on specialty-tier brand drugs. For patients without insurance coverage for Vyleesi, compounding eliminates the need to manage prior authorizations entirely.

Safety Considerations Specific to Compounded Bremelanotide

The adverse effect profile of bremelanotide is well established from the RECONNECT program. Nausea was the most common side effect, occurring in 40% of bremelanotide-treated patients versus 1% on placebo. The nausea is typically transient, peaking within 1 to 2 hours and resolving within 3 to 4 hours (Kingsberg et al., Obstet Gynecol, 2019). Flushing (20%), injection site reactions (13%), and headache (11%) were also reported.

Blood pressure. Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg and a decrease in heart rate of approximately 5 bpm. The FDA labeling contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease. Prescribers should document a baseline blood pressure reading before initiating therapy.

Hyperpigmentation. Melanocortin receptor agonism can darken skin, particularly the face, gingiva, and breasts. In the RECONNECT trials, focal hyperpigmentation occurred in about 1% of patients. This effect is generally reversible after discontinuation but may take weeks to months to resolve.

These safety parameters apply identically to compounded bremelanotide because the adverse effects are molecule-dependent, not formulation-dependent. One compounding-specific risk is dosing accuracy: if a multi-dose vial is prepared at an incorrect concentration, patients could receive too much or too little drug. This is why COA verification matters.

Bremelanotide vs. Flibanserin: Which Is the Better Value?

Bremelanotide and flibanserin (Addyi) are the only two FDA-approved treatments for premenopausal HSDD. They work by different mechanisms and have different use patterns.

| Parameter | Bremelanotide | Flibanserin | |---|---|---| | Mechanism | Melanocortin-4 receptor agonist | 5-HT1A agonist / 5-HT2A antagonist | | Dosing | As needed, subcutaneous | Daily, oral | | Alcohol restriction | None | Absolute contraindication with alcohol | | Brand cost | ~$1,200/month | ~$400 to $800/month | | Compounded cost | ~$140/month | ~$30 to $60/month | | Onset | 45 minutes before activity | 4 to 8 weeks for full effect |

For women who prefer on-demand dosing and do not want a daily pill, bremelanotide is the better fit. For women who want a daily oral option and do not drink alcohol, flibanserin may be more practical. The HSDD treatment guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) recommend shared decision-making based on patient preference, comorbidities, and cost (Parish et al., J Sex Med, 2021).

The Regulatory Outlook for Compounded Bremelanotide

FDA enforcement discretion toward compounded peptides has tightened since 2023. The agency added tirzepatide and semaglutide to its shortage list and later removed them, which triggered compounding restrictions for those molecules. Bremelanotide has not been placed on the FDA drug shortage list, and Palatin has not petitioned the FDA to restrict compounding of the molecule.

If a generic bremelanotide eventually reaches market through the ANDA pathway, compounding could face economic pressure but not legal prohibition. Under 503A, pharmacies may compound any commercially available drug if they can demonstrate a clinical difference (e.g., a different concentration, preservative-free formulation, or combined preparation). Under 503B, the calculus depends on whether FDA enforcement shifts.

For now, patients and prescribers can access compounded bremelanotide without legal ambiguity. Programs do change, so verify current availability with your pharmacy and prescriber before assuming continued access.

What to Expect at Your First Appointment

A bremelanotide evaluation at a telehealth clinic typically lasts 15 to 25 minutes. The clinician will ask about duration and context of low desire, screen for depression and relationship distress using validated tools, review your medication list for desire-suppressing drugs (SSRIs, hormonal contraceptives, antiandrogens), and take or request a recent blood pressure reading.

If bremelanotide is appropriate, the prescriber writes a compounding prescription and counsels on self-injection technique. The subcutaneous injection is given in the abdominal fat using a 27- to 30-gauge needle, similar to insulin. Most patients report the injection itself as painless; the nausea that follows is the primary tolerability challenge.

A follow-up at 4 to 6 weeks assesses response. The clinical threshold used in the RECONNECT trials was a ≥1 increase in SSEs per month and a ≥5-point decrease in FSDS-DAO score. Patients who do not respond after 8 doses are unlikely to benefit from continued use.